Compare PDX & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDX | ESPR |
|---|---|---|
| Founded | 2019 | 2008 |
| Country | NY | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 904.4M | 731.9M |
| IPO Year | N/A | 2013 |
| Metric | PDX | ESPR |
|---|---|---|
| Price | $20.47 | $2.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | 140.7K | ★ 6.5M |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | ★ 4.95% | N/A |
| EPS Growth | N/A | ★ 60.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $403,135,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 21.31 |
| 52 Week Low | $18.47 | $0.73 |
| 52 Week High | $25.25 | $4.18 |
| Indicator | PDX | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 38.90 | 32.79 |
| Support Level | $19.95 | $1.02 |
| Resistance Level | $22.29 | $2.08 |
| Average True Range (ATR) | 0.45 | 0.20 |
| MACD | -0.15 | -0.03 |
| Stochastic Oscillator | 3.39 | 3.34 |
PIMCO Dynamic Income Strategy Fund is a non-diversified, limited-term, closed-end management investment company. It seeks current income as a primary objective and capital appreciation as a secondary objective. The fund makes investments using a dynamic asset allocation plan among multiple sectors in the public and private credit markets globally, including corporate debt, mortgage-related and other asset-backed instruments, government and sovereign debt, taxable municipal bonds, and other fixed, variable, and floating-rate income-producing securities of U.S. and foreign issuers, including emerging market issuers and real estate-related investments.
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.